Agios Pharmaceuticals (AGIO) Long-Term Investments (2013 - 2026)

Agios Pharmaceuticals (AGIO) has 14 years of Long-Term Investments data on file, last reported at $347.3 million in Q2 2026.

• Quarterly Long-Term Investments fell 13.29% year-over-year to $347.3 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $347.3 million (down 13.29% YoY) and the FY2025 annual result came in at $310.0 million, down 51.43% from the prior year.
• Long-Term Investments rose to $347.3 million in Q2 2026, from $308.5 million in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $655.9 million in Q3 2024 to a low of $29.4 million in Q4 2023.
• A 5-year average of $311.5 million and a median of $301.3 million in 2022 frame the typical range for Long-Term Investments.
• Annual changes were most pronounced in 2023 — Long-Term Investments slumped 90.62% — and 2024, when it soared 2068.58%.
• Tracing AGIO's Long-Term Investments over 5 years: stood at $313.9 million in 2022, then tumbled by 90.62% to $29.4 million in 2023, then soared by 2068.58% to $638.3 million in 2024, then tumbled by 51.43% to $310.0 million in 2025, then rose by 12.01% to $347.3 million in 2026.
• The last three Long-Term Investments figures came in at $347.3 million (Q2 2026), $308.5 million (Q1 2026), and $310.0 million (Q4 2025), per Business Quant data.